Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in LAD1
NCT03366142Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2018
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ustekinumab in Leukocyte Adhesion Deficiency Type 1 (LAD1), sponsored by National Institute of Allergy and Infectious Diseases. Started Jul 2018; status: completed.
02
Drugs
ustekinumab
03
Conditions
Leukocyte Adhesion Deficiency Type 1 (LAD1)
Beyond the preview
Go deeper on NCT03366142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366142.